How do I know if failed transfers point to the embryo or the uterine environment?
The distinction between embryo-side and uterine-side failure cannot be made with certainty after a single transfer. The statistical starting point matters: even the best-quality embryos fail to implant approximately 30–40 percent of the time. One failed transfer is not evidence of a problem; it is within the expected range of outcomes.
The pattern that triggers a deeper investigation is two or more consecutive transfer failures with embryos that were either morphologically high-quality (4AA or equivalent grading) or genetically tested and confirmed euploid. This pattern, sometimes called recurrent implantation failure (RIF), shifts the probability toward uterine or immune factors as the primary variable.
Clinical signals that favor a uterine or receptivity diagnosis over egg quality:
- Euploid embryos failing to implant (chromosomal normalcy has already been confirmed)
- Embryos that developed well in culture but did not produce a positive beta-hCG or produced a very brief chemical pregnancy (implantation initiated but did not sustain)
- A pattern of negative transfers without any early pregnancy signal at all, versus transfers that produce a positive pregnancy test that quickly declines
Clinical signals that favor an egg quality contribution even in transferred “good” embryos:
- PGT-A has not been performed and morphological grading was the quality metric
- Prior cycles showed poor blastocyst conversion alongside the transfers that failed
- Age over 38, where non-chromosomal egg quality factors (mitochondrial, epigenetic) increasingly affect embryo competence beyond what PGT-A captures
What is the endometrial receptivity piece, and how is it tested?
Endometrial receptivity refers to the specific window during the luteal phase when the uterine lining is biochemically prepared to accept and sustain an embryo. In most women this window occurs approximately five to six days after progesterone begins. In some women, the window is shifted earlier or later than standard protocols assume, and an embryo transferred on the “standard” protocol day arrives outside the receptive window.
This is the clinical basis for the Endometrial Receptivity Array (ERA) test, a molecular analysis of endometrial biopsy tissue that identifies whether a woman’s window of implantation is on-time, pre-receptive (window is later than standard), or post-receptive (window is earlier). In women with displaced windows, adjusting the transfer timing by one to two days based on ERA results significantly improves implantation rates.
A 2021 prospective study in Fertility and Sterility found that ERA-guided personalized embryo transfer improved live birth rates by 25 percent compared to standard timing in women with two or more prior failed transfers.
Additional endometrial evaluation that is often warranted before attributing failure to embryo quality:
- Hysteroscopy: Direct visualization of the uterine cavity to identify polyps, fibroids, adhesions, or septum that may not appear on ultrasound
- Endometrial biopsy with CD138 staining: Rules out chronic endometritis
- Progesterone on transfer day: Confirms adequate progesterone for the transfer timing
What immune factors can prevent implantation with good embryos?
Implantation requires a carefully regulated immune response in which the maternal immune system tolerates the genetically foreign embryo rather than rejecting it. When this tolerance mechanism fails, immune-mediated implantation failure occurs even when the embryo itself is chromosomally normal and morphologically excellent.
The primary immune mechanisms in recurrent implantation failure:
Natural killer (NK) cell activity. Uterine NK cells play a regulatory role in implantation under normal conditions. When NK cell activity is elevated beyond the range compatible with trophoblast invasion, implantation fails. Peripheral blood NK cell testing and uterine NK cell biopsy can quantify activity levels. Elevated uterine NK activity is treated with low-dose prednisolone, intralipid infusion, or other immunomodulatory protocols in specialist centers.
Antiphospholipid syndrome (APS). Antiphospholipid antibodies interfere with the phospholipid components of trophoblast cell membranes, impairing the embryo’s ability to implade into the endometrium. APS is diagnosed by testing for lupus anticoagulant, anticardiolipin antibodies (IgG and IgM), and anti-beta2-glycoprotein-I antibodies. Treatment with low-dose aspirin and low-molecular-weight heparin significantly improves implantation outcomes in confirmed APS.
Elevated TNF-alpha and inflammatory cytokines. Systemic inflammation, whether from gut dysbiosis, autoimmune activity, or metabolic dysfunction, elevates cytokine levels in the endometrial environment. Elevated TNF-alpha specifically impairs trophoblast differentiation. This is one mechanism through which systemic inflammatory conditions (unresolved gut dysbiosis, thyroid autoimmunity, insulin resistance) affect implantation even when transferred embryos appear high-quality.
When does egg quality still matter even with a “good” embryo?
Chromosomal normalcy, confirmed by PGT-A, rules out aneuploidy but does not rule out all egg quality contributions to implantation failure. PGT-A tests chromosome number; it does not evaluate mitochondrial DNA quality, epigenetic programming, cytoplasmic organization, or metabolic sufficiency of the oocyte. These non-chromosomal dimensions of egg quality can affect embryo implantation potential without appearing in genetic testing results.
Specific non-chromosomal quality factors that affect implantation:
- Mitochondrial DNA quantity and quality: Oocytes with high mitochondrial DNA copy numbers have been associated with higher implantation rates in euploid transfers in multiple studies. PGT-A does not assess mitochondrial quality.
- Cytoplasmic maturity: The oocyte cytoplasm contains the proteins, organelles, and signaling molecules that direct early embryo development. Eggs that were immature at retrieval or that responded poorly to triggering may have cytoplasmic limitations not captured by post-fertilization morphological grading.
- Epigenetic programming: Oocyte maturation includes the erasure and re-establishment of epigenetic marks that govern gene expression in the developing embryo. Oxidative stress, endocrine disruptor exposure, and metabolic dysfunction during maturation can disrupt epigenetic programming in ways that impair implantation or early development without producing chromosomal abnormality.
This means that egg quality optimization in the 90-day pre-retrieval window remains relevant even for women who will transfer PGT-A-tested embryos. Chromosomal testing screens for the most common cause of failure; it does not address the full spectrum of egg quality variables.
What should I investigate after multiple failed transfers with good embryos?
A systematic investigation after two or more failed transfers with morphologically good or euploid embryos should cover both uterine and immunological variables before the next transfer. Adding more transfers without additional evaluation is unlikely to produce different outcomes.
The recurrent implantation failure workup:
- Hysteroscopy: Direct visualization rules out intrauterine pathology (polyps, fibroids, adhesions, septum) that ultrasound may miss. This is the first-line anatomical evaluation.
- Endometrial biopsy with CD138 staining: Identifies chronic endometritis. If positive, targeted antibiotic treatment (typically doxycycline or combined antibiotic protocol) clears CE in most cases before the next transfer.
- ERA test: Identifies displaced window of implantation. Most valuable in women who have had two or more failed transfers and have no identified structural or infectious cause.
- Progesterone on transfer day: Request a serum progesterone level on the scheduled transfer day. Target above 10 ng/mL as a minimum; above 20 ng/mL is associated with significantly higher live birth rates. If progesterone is low, adjusting supplementation protocol before the next transfer is a straightforward intervention.
- Immune evaluation: Antiphospholipid antibody panel (lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta2-glycoprotein-I), peripheral blood NK cell levels, and thyroid antibodies (TPO and TgAb, as thyroid autoimmunity is associated with implantation failure independent of TSH levels).
- Sperm DNA fragmentation: If not previously tested and the embryo quality appeared good through development, high sperm DNA fragmentation can contribute to implantation failure through post-EGA mechanisms.
The The Fertility Intelligence Hub Perspective
The question I am asked in some form more often than almost any other is: “If the embryo was good, why didn’t it work?” And the honest answer is that a good embryo and a successful transfer are not the same thing. The embryo is one half of the equation. The environment it is transferred into is the other half.
What I find, consistently, is that recurrent implantation failure in women with morphologically good or even euploid embryos is often investigated in the wrong direction. More egg quality work gets prescribed, another cycle begins, another transfer fails. What gets missed is the endometrial evaluation: has anyone looked inside the uterus directly? Has anyone tested for chronic endometritis? Has anyone checked progesterone on transfer day?
Chronic endometritis is one of the most treatable findings in reproductive medicine. It resolves with a course of antibiotics. And it is present in somewhere between 15 and 30 percent of women with recurrent implantation failure. That is not a rare finding. It is a common one that requires a specific test to catch.
Inside The Egg Awakening, I approach implantation failure as a systems question, not an egg quality verdict. The embryo, the endometrium, the immune environment, the progesterone level on transfer day, the systemic inflammatory load: all of these are part of the answer. When we investigate the full system, the path forward usually becomes clearer than “try again and hope for better luck.”
